Nurix Therapeutics, Inc.
NRIX
$15.96
-$0.32-1.97%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -54.70% | -33.60% | -76.53% | 2.43% | -35.73% |
| Total Depreciation and Amortization | -8.53% | 34.23% | 20.60% | 24.59% | 6.17% |
| Total Amortization of Deferred Charges | -- | -53.85% | -- | -- | -- |
| Total Other Non-Cash Items | 46.87% | 44.83% | 42.01% | 14.93% | -12.34% |
| Change in Net Operating Assets | 127.79% | -445.21% | 709.44% | -447.14% | -37.36% |
| Cash from Operations | -17.72% | -39.14% | -36.06% | -59.08% | -45.62% |
| Capital Expenditure | 70.01% | -143.75% | -15.51% | -38.10% | -20.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -523.12% | 103.95% | 380.04% | 157.44% | -24.43% |
| Cash from Investing | -584.96% | 100.25% | 336.54% | 154.55% | -28.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,256.08% | 17.70% | -97.48% | -100.00% | -9.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,256.08% | 17.70% | -97.48% | -100.00% | -9.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -415.73% | 1,438.59% | 67.57% | -87.54% | -607.96% |